Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sagent Pharmaceuticals Inc reaffirms FY 2014 guidance


Tuesday, 6 May 2014 07:00am EDT 

Sagent Pharmaceuticals Inc:Anticipates FY 2014 Net revenue for the year to be in the range of $250 to $290 million.Anticipates reported net income for FY 2014 to be in the range of a $10 million loss to $10 million in earnings.FY 2014 revenue of $273 million and net income of $4 million - Thomson Reuters I/B/E/S. 

Company Quote

28.82
0.42 +1.48%
26 Nov 2014